SEARCH

SEARCH BY CITATION

References

  • 1
    Netzel-Arnett S, Hooper JD, Szabo R et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metast Rev 2003; 22: 22336.
  • 2
    List K, Szabo R, Molinolo A, Sriuranpong V et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 2005; 19: 193450.
  • 3
    Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004; 6: 18595.
  • 4
    Vasioukhin V. Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle 2004; 3: 13947.
  • 5
    Stephan C, Yousef GM, Scorilas A et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 2004; 171: 18791.
  • 6
    Xuan JA, Schneider D, Toy P et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res 2006; 66: 361119.
  • 7
    Tanimoto H, Yan Y, Clarke J et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 1997; 57: 28847.
  • 8
    Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36 720–5.
  • 9
    Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26 333–42.
  • 10
    Kazama Y, Hamamoto T, Foster DC, Kisiel W. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem 1995; 270: 6672.
  • 11
    Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 2005; 579: 194550.
  • 12
    Jiang WG, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999; 29: 20948.
  • 13
    Kataoka H, Miyata S, Uchinokura S, Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metast Rev 2003; 22: 22336.
  • 14
    Kataoka Itoh H, Hamasuna R, Meng JY, Koono M. Pericellular activation of hepatocyte growth factor/scatter factor (HGF/GF) in colorectal carcinomas: roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1). Hum Cell 2001; 16: 8393.
  • 15
    Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M. Activation of hepatocyte growth factor/scatter in colorectal carcinoma. Cancer Res 2000; 60: 614859.
  • 16
    Tjin EP, Derksen PW, Kataoka H, Spaargaren M, Pals ST. Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 2004; 104: 21725.
  • 17
    Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hasui Y, Osada Y. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J Urol 2004; 171: 8906.
  • 18
    Shimomura T, Kondo J, Ochiai M et al. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem 1993; 268: 22 927–32.
  • 19
    Kataoka H, Shimomura T, Kawaguchi T et al. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000; 275: 40 453–62.
  • 20
    Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999; 274: 18 237–42.
  • 21
    Kawaguchi T, Qin L, Shimomura T et al. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 27 558–64.
  • 22
    Delaria KA, Muller DK, Marlor CW et al. Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 1997; 272: 12 209–14.
  • 23
    Hamasuna R, Kataoka H, Meng JY et al. Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells. Int J Cancer 2001; 93: 33945.
  • 24
    Fukai K, Yokosuka O, Chiba T et al. Hepatocyte growth factor activator inhibitor 2/placental bikunin HAI-2/PB gene is frequently hypermethylated in human hepatocellular carcinoma. Cancer Res 2003; 63: 86749.
  • 25
    Tanaka H, Nagaike K, Takeda N et al. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta. Mol Cell Biol 2005; 25: 568798.
  • 26
    Mitchell KJ, Pinson KI, Kelly OG et al. Functional analysis of secreted and transmembrane proteins critical to mouse development. Nat Genet 2001; 28: 2419.
  • 27
    Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183: 1313.
  • 28
    Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 6873.
  • 29
    Foster K, Prowse A, Van Den Berg A et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal cell carcinoma. Hum Mol Genet 1994; 3: 216973.
  • 30
    Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 97004.
  • 31
    Horie S, Aruga S, Kawamata H, Okui N, Kakizoe T, Kitamura T. Biological role of HGF/MET pathway in renal cell carcinoma. J Urol 1999; 161: 9907.
  • 32
    Koochekpour S, Jeffers M, Wang PH et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999; 19: 590212.
  • 33
    Tsuji A, Torres-Rosado A, Arai T et al. Hepsin, a cell membrane-associated protease. J Biol Chem 1991; 266: 16 948–53.
  • 34
    Eble JN, Sauter G, Epstein JI et al. World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. Lyons: IARC Press; 2004.
  • 35
    American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th edn. Philadelphia: Lippincott-Raven; 2002.
  • 36
    Muraoka K, Kataoka H, Nabeshima K et al. Establishment and characterization of a human renal cell carcinoma cell line MRT-1, with special reference to the production of serine proteinase inhibitors. Hum Cell 1995; 8: 1118.
  • 37
    Uchinokura S, Miyata S, Fukushima T et al. Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo. Int J Cancer 2006; 118: 58392.
  • 38
    Torres-Rosado A, O'Shea KS, Tsuji A, Chou SH, Kurachi K. Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc Natl Acad Sci USA 1993; 90: 71815.
  • 39
    Zacharski LR, Ornstein DL, Memoli VA, Rousseau SM, Kisiel W. Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma. Thromb Haemost 1998; 79: 8767.
  • 40
    Roemer A, Schwettmann L, Jung M et al. The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? J Urol 2004; 172: 21626.
  • 41
    Herter S, Piper DE, Aaron W et al. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 2005; 390: 12536.
  • 42
    Jin JS, Chen A, Hsieh DS, Yao CW, Cheng MF, Lin YF. Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol 2006; 14: 6572.
  • 43
    Kataoka H, Itoh H, Uchino H et al. Conserved expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin in human colorectal carcinomas. Cancer Lett 2000; 148: 12734.
  • 44
    Muller-Pillasch F, Wallrapp C, Bartels K et al. Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. Biochim Biophys Acta 1998; 1395: 8895.
  • 45
    Morris MR, Gentle D, Abdulrahman M et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/spint2 in papillary and clear renal cell carcinoma. Cancer Res 2005; 65: 4598606.